Skip to content

Clinical Study on Li-Lu-Gan-Cao-Fang with Anti Parkinson's Drugs for the Treatment of Parkinson's Disease with Wind Phlegm Blocking the Orifice Type

Clinical Study on Li-Lu-Gan-Cao-Fang with Anti Parkinson's Drugs for the Treatment of Parkinson's Disease with Wind Phlegm Blocking the Orifice Type

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2024000786
Enrollment
Unknown
Registered
2024-12-11
Start date
2025-01-01
Completion date
Unknown
Last updated
2025-03-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Parkinsons Disease

Interventions

the treatment group:On the basis of anti-PD medication treatment with the Li-Lu-Gan-Cao-Fang
the control group:anti-PD medication treatment

Sponsors

Beijing Hospital of Integrated Traditional Chinese and Western Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
50 Years to 85 Years

Inclusion criteria

Inclusion criteria: 1.Patients who meet the Western medical diagnostic criteria for Parkinson's disease and the traditional Chinese medicine diagnostic criteria for tremor syndrome with wind-phlegm obstructing the orifices. 2.Patients aged between 50 and 85 years inclusive. 3.Patients with a modified Hoehn and Yahr (H&Y) scale score of =3. 4.Patients who have been on stable anti-parkinsonian medication for more than one month and are newly diagnosed with Parkinson's disease (PD). 5.Patients who are not currently taking TCM medications at the time of enrollment; if they have previously taken TCM medications they must have discontinued their use for at least one month or more. 6.Patients who voluntarily participate and provide informed consent.

Exclusion criteria

Exclusion criteria: 1.Patients with secondary parkinsonism syndrome. 2.Patients with significant comorbidities moderate to severe hepatic or renal dysfunction or severe infections. 3.Patients with a known allergy to the medications required for this trial. 4.Patients with moderate to severe dementia or psychiatric disorders that preclude effective communication. 5.Patients who have participated in other clinical drug trials within the last 3 months.

Design outcomes

Primary

MeasureTime frame
39-item Parkinson's disease questionnairePDQ-39;Unified Parkinson's disease rating scaleUPDRS;

Secondary

MeasureTime frame
Magnetic resonance spectroscopy;Traditional Chinese Medicine (TCM) Symptom Grading and Quantitative Scoring Standard for PD Patients;interleukin-6;Uric acid;Homocysteine;

Countries

CHINA

Contacts

Public ContactHao wenjie

Beijing Hospital of Integrated Traditional Chinese and Western Medicine

hwjzxykf@sina.com15101161576

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026